Literature DB >> 16312261

Oxidative stress and non-enzymatic glycation in IgA nephropathy.

T Vas1, Z Wagner, V Jenei, Z Varga, T Kovács, I Wittmann, R Schinzel, G Balla, J Balla, A Heidland, J Nagy.   

Abstract

AIM: Approximately 20-50% of IgA nephropathy patients develop end-stage renal disease. We have previously found enhanced oxidative stress and decreased antioxidant capacity in red blood cells of IgA nephropathy patients. In this study we assess oxidative stress, non-enzymatic glycation, oxidative resistance of low-density lipoprotein and its alpha-tocopherol content in these patients. PATIENTS AND METHODS: Non-enzymatic glycation and oxidative stress were assessed in 88 IgA nephropathy patients by measuring advanced glycation end products, Nepsilon-carboxymethyl-lysine, thiobarbituric acid reactive substances, oxidative resistance of low-density lipoprotein and its alpha-tocopherol content.
RESULTS: Advanced glycation end products (2659 +/- 958 a.u.) and Nepsilon-carboxymethyl-lysine (563 +/- 215 ng/ml) were significantly higher in IgA nephropathy patients with decreased renal function compared to those with normal renal function (p < 0.002) or controls (p < 0.001). Thiobarbituric acid-reactive substances in plasma and associated with low-density lipoprotein were significantly elevated and oxidative resistance of low-density lipoprotein was significantly reduced in all groups of IgA nephropathy patients. There was no significant difference in circulating fluorescent advanced glycation end products, Nepsilon-carboxymethyl-lysine, thiobarbituric acid-reactive substances levels, oxidative resistance of low-density lipoprotein and its alpha-tocopherol content between patients with normal vs. impaired glucose metabolism. Low alpha-tocopherol content of low-density lipoprotein was accompanied with decreased oxidative resistance, depletion in polyunsaturated fatty acids, elevated saturated fatty acids and thiobarbituric acid-reactive substances within low-density lipoprotein suggesting enhanced lipid peroxidation.
CONCLUSIONS: Decreased oxidative resistance of low-density lipoprotein and enhanced oxidative stress are common features in IgA nephropathy, while increased non-enzymatic glycation occurs as renal function declines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16312261     DOI: 10.5414/cnp64343

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

1.  Prognostic impact of serum bilirubin level on long-term renal survival in IgA nephropathy.

Authors:  Shigeru Tanaka; Toshiharu Ninomiya; Kosuke Masutani; Masaharu Nagata; Akihiro Tsuchimoto; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  Clin Exp Nephrol       Date:  2015-02-21       Impact factor: 2.801

2.  Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy.

Authors:  Roberta Camilla; Hitoshi Suzuki; Valentina Daprà; Elisa Loiacono; Licia Peruzzi; Alessandro Amore; Gian Marco Ghiggeri; Gianna Mazzucco; Francesco Scolari; Ali G Gharavi; Gerald B Appel; Stéphan Troyanov; Jan Novak; Bruce A Julian; Rosanna Coppo
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

3.  Oxidative stress and macrophage infiltration in IgA nephropathy.

Authors:  Yasar Caliskan; Erol Demir; Ecem Karatay; Yasemin Ozluk; Safak Mirioglu; Ahmet Burak Dirim; Ayse Serra Artan; Sebahat Usta Akgul; Ozgur Akin Oto; Fatma Savran Oguz; Aydin Turkmen; Krista L Lentine; Halil Yazici
Journal:  J Nephrol       Date:  2021-11-16       Impact factor: 3.902

4.  Intermedin ameliorates IgA nephropathy by inhibition of oxidative stress and inflammation.

Authors:  Yanhong Wang; Jihua Tian; Haixiu Guo; Yang Mi; Ruijing Zhang; Rongshan Li
Journal:  Clin Exp Med       Date:  2015-04-28       Impact factor: 3.984

5.  Immunogenicity of advanced glycation end products in diabetic patients and in nephropathic non-diabetic patients on hemodialysis or after renal transplantation.

Authors:  A M Buongiorno; S Morelli; E Sagratella; R Cipriani; S Mazzaferro; S Morano; M Sensi
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

6.  Unchanged serum levels of advanced glycation endproducts in patients with liver disease.

Authors:  Moritz Butscheid; Christian Schäfer; Stefanie Brenner; Dominik Alscher; Thomas Mürdter; Toshimitsu Niwa; Matthias Frischmann; Monika Pischetsrieder; Ulrich Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-06-15       Impact factor: 3.195

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.